UNSPSC 51285901: Benurestat

This classification denotes an enzyme inhibitor with the molecular formula C9H9ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9RA9A22Z0W, chemically known as benzamide, 4-chloro-n-(2-(hydroxyamino)-2-oxoethyl)- but more generally known as benurestat, which bears US NIH Compound Identifier 38000. European Medicines Agency schedules Benurestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05738MIG.

The term BENURESTAT is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). BENURESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1CCC(C(=O)NCC(=O)NO)CC1.

UNSPSC 51285901 Benurestat is a Commodity code that covers pharmaceutical products and medical supplies, but state and local governments under recent activity are actually procuring naloxone, drug deactivation systems, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The code captures both direct pharmaceutical procurement and broader medical supply sourcing activities that support public health and emergency services operations. State and local issuing bodies pursuing this code include county health departments (Seminole County, Florida), fire departments and municipal procurement offices (City of Tampa), state health and human services agencies (Texas HHS Commission), and regional cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance). These jurisdictions range from individual counties managing community health initiatives to statewide systems coordinating pharmaceutical supply chains across multiple government facilities.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with cooperative purchasing vehicles becoming a significant sourcing model for state and local pharmaceutical procurement. Representative opportunities include Seminole County's invitation for bids (IFB 60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to community health facilities; the City of Tampa's sealed-bid solicitation (26P00145, due March 13, 2026) for 169 line items of medical and first aid supplies supporting the Tampa Fire Department Rescue Division, estimated at $700,000 and designated as sheltered for certified Small Local Business Enterprises with a 5 percent bid discount; the Texas HHS Commission's request for information (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription programs and vendor capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance's request for proposal (S1070000015802, due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026.